In addition, SGLT2 inhibitor EMPA also improves myocardial insulin sensitivity and glucose utilization by modulating diabetes-related increases in MAPKs and dysregulation of insulin receptor substrate 1 and Akt phosphorylation [136], thereby benefiting the improvement of myocardial hypertrophy and fibrosis. This evidence concerns the gene AKT1 and cardiac hypertrophy.